[Preliminary experience with achieving immune tolerance in patients with hemophilia A and circulating factor VIII inhibitor].
The appearance of antibodies to factor VIII is a serious complication in the treatment of haemophilia A. A protocol is presented aiming at suppression of the anticoagulant using continued treatment with factor VIII (25 u/kg b.w. twice weekly). Ten patients with previous maximal factor VIII antibody titre from 7 to 2900 Bethesda units were treated. So far the inhibitor was eradicated in 3 cases treated continuously for from 5 to 20 months. In two of these three cases successful surgical procedures were performed without anamnestic response.
Scharf
R
R
Klinika Chirurgiczna, Instytut Hematologii, Warszawa.
Kucharski
W
W
Lopaciuk
S
S
Celińska
W
W
Dmytrow
A
A
Domański
K
K
Gonet
S
S
Miastkowski
Z
Z
Nowakowska
I
I
Przybylski
A
A
D000293:Adolescent; D000328:Adult; D001323:Autoantibodies / Q000276:immunology*; D001327:Autoimmune Diseases / Q000097:blood / Q000276:immunology* / Q000628:therapy; D001803:Blood Transfusion; D002648:Child; D005169:Factor VIII / Q000008:administration & dosage* / Q000276:immunology*; D005340:Fibrinogen / Q000008:administration & dosage*; D006467:Hemophilia A / Q000097:blood / Q000276:immunology* / Q000628:therapy; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology; D008297:Male; D008875:Middle Aged
D001323:Autoantibodies; C026912:cryoprecipitate coagulum; D005169:Factor VIII; D005340:Fibrinogen
Wstepne doświadczenia w uzyskiwaniu tolerancji immunologicznej u chorych na hemofilie A z krazacym antykoagulantem.